Advertisement

Journal of Pharmacokinetics and Pharmacodynamics

, Volume 34, Issue 5, pp 687–709 | Cite as

Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice

  • Amit Garg
  • Joseph P. Balthasar
Article

Abstract

Although it is known that FcRn, the neonatal Fc-receptor, functions to protect immune gamma globulin (IgG) from elimination, the influence of FcRn on the tissue distribution of IgG has not been quantified. In the present work, a physiologically-based pharmacokinetic (PBPK) model has been developed to characterize and predict IgG disposition in plasma and in tissues. The model includes nine major compartments, connected in an anatomical manner, to represent tissues known to play a significant role in IgG disposition. Each tissue compartment was subdivided into vascular, endosomal and interstitial spaces. IgG transport between the blood and interstitial compartments may proceed by convection through paracellular pores in the vascular endothelium, or via FcRn-mediated transcytosis across vascular endosomal cells. The model was utilized to characterize plasma concentration-time data for 7E3, a monoclonal antiplatelet IgG1 antibody, in control and FcRn-knockout (KO) mice. These data showed that high dose intravenous immunoglobulin (IVIG), 1g/kg, increased 7E3 clearance in control mice from 5.2 ± 0.3 to 14.4 ± 1.4 ml/d/kg; however, IVIG failed to increase the clearance of 7E3 in KO mice (72.5 ± 4.0 vs. 61.0 ± 3.6 ml/d/kg). Based on model fitting to the 7E3 plasma concentration data, simulations were conducted to predict tissue concentrations of IgG in control and in KO mice, and the predictions were then tested by assessing 7E3 tissue distribution in KO mice and control mice. 7E3 was radiolabeled with Iodine-125 using chloramine T method, and 125I-7E3 IgG was administered at a dose of 8 mg/kg to control and KO mice. At various time points, sub-groups of 3 mice were sacrificed, blood and tissue samples were collected, and radioactivity assessed by gamma counting. PBPK model performance was assessed by comparing model predictions with the observed data. The model accurately predicted 7E3 tissue concentrations, with mean predicted vs. observed AUC ratios of 1.04 ± 0.2 and 0.86 ± 0.3 in control and FcRn-KO mice. The PBPK model, which incorporates the influence of FcRn on IgG clearance and disposition, was found to provide accurate predictions of IgG tissue kinetics in control and FcRn-knockout mice.

Keywords

PBPK Pharmacokinetics Neonatal Fc receptor FcRn IgG Antibody 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Reichert J and Pavolu A (2004). Monoclonal antibodies market. Nat Rev Drug Discov 3: 383–384 PubMedCrossRefGoogle Scholar
  2. Paul WE (2003). Fundamental immunology. Lippincott Williams & Wilkins, Philadelphia Google Scholar
  3. Waldmann TA and Strober W (1969). Metabolism of immunoglobulins. Prog Allergy 13: 1–110 PubMedGoogle Scholar
  4. Brambell FW, Hemmings WA and Morris IG (1964). A Theoretical Model of Gamma-Globulin Catabolism. Nature 203: 1352–1354 PubMedCrossRefGoogle Scholar
  5. Jones EA and Waldmann TA (1972). The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest 51: 2916–2927 PubMedGoogle Scholar
  6. Rodewald R (1973). Intestinal transport of antibodies in the newborn rat. J Cell Biol 58: 189–211 PubMedCrossRefGoogle Scholar
  7. Raghavan M and Bjorkman PJ (1996). Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol 12: 181–220 PubMedCrossRefGoogle Scholar
  8. Rodewald R (1976). pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol 71: 666–669 PubMedCrossRefGoogle Scholar
  9. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y and Ward ES (1996). Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26: 690–696 PubMedCrossRefGoogle Scholar
  10. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D and Simister NE (1996). Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 89: 573–578 PubMedCrossRefGoogle Scholar
  11. Junghans RP and Anderson CL (1996). The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93: 5512–5516 PubMedCrossRefGoogle Scholar
  12. Dall’ Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA and Langermann S (2002). Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169: 5171–5180 Google Scholar
  13. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ and Ward ES (1997). Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 15: 637–640 PubMedCrossRefGoogle Scholar
  14. Borvak J, Richardson J, Medesan C, Antohe F, Radu C, Simionescu M, Ghetie V and Ward ES (1998). Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol 10: 1289–1298 PubMedCrossRefGoogle Scholar
  15. Ghetie V and Ward ES (1997). FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 18: 592–598 PubMedCrossRefGoogle Scholar
  16. Israel EJ, Taylor S, Wu Z, Mizoguchi E, Blumberg RS, Bhan A and Simister NE (1997). Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 92: 69–74 PubMedCrossRefGoogle Scholar
  17. Baxter LT, Zhu H, Mackensen DG and Jain RK (1994). Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54: 1517–1528 PubMedGoogle Scholar
  18. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, Blumberg RS and Lencer WI (1999). Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 104: 903–911 PubMedGoogle Scholar
  19. Lobo ED, Hansen RJ and Balthasar JP (2004). Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93: 2645–2668 PubMedCrossRefGoogle Scholar
  20. Tang L, Persky AM, Hochhaus G and Meibohm B (2004). Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93: 2184–2204 PubMedCrossRefGoogle Scholar
  21. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ and Weinstein JN (1986). Pharmacokinetics of monoclonal immunoglobulin G1, F(ab’)2, and Fab’ in mice. Cancer Res 46: 3969–3978 PubMedGoogle Scholar
  22. Baxter LT, Zhu H, Mackensen DG, Butler WF and Jain RK (1995). Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 55: 4611–4622 PubMedGoogle Scholar
  23. Friedrich SW, Lin SC, Stoll BR, Baxter LT, Munn LL and Jain RK (2002). Antibody-directed effector cell therapy of tumors: analysis and optimization using a physiologically based pharmacokinetic model. Neoplasia 4: 449–463 PubMedCrossRefGoogle Scholar
  24. Ismail M, Abd-Elsalam MA and Al-Ahaidib MS (1998). Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB’)2 and F(AB) of the antivenin. Toxicon 36: 93–114 PubMedCrossRefGoogle Scholar
  25. Zhu H, Baxter LT and Jain RK (1997). Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. J Nucl Med 38: 731–741 PubMedGoogle Scholar
  26. Zhu H, Melder RJ, Baxter LT and Jain RK (1996). Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. Cancer Res 56: 3771–3781 PubMedGoogle Scholar
  27. Varner JA, Nakada MT, Jordan RE and Coller BS (1999). Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro). Angiogenesis 3: 53–60 PubMedCrossRefGoogle Scholar
  28. Jensenius JC and Williams AF (1974). The binding of anti-immunoglobulin antibodies to rat thymocytes and thoracic duct lymphocytes. Eur J Immunol 4: 91–97 PubMedCrossRefGoogle Scholar
  29. Hansen RJ and Balthasar JP (2002). Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. [see comment]. Thromb Haemost 88: 898–899 PubMedGoogle Scholar
  30. Bailer AJ (1998). Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16: 303–309 CrossRefGoogle Scholar
  31. Nedelman JR, Gibiansky E and Lau DT (1995). Applying Bailer’s method for AUC confidence intervals to sparse sampling. Pharm Res 12: 124–128 PubMedCrossRefGoogle Scholar
  32. Motulsky H (1995). Intuitive biostatistics. Oxford University Press, New York Google Scholar
  33. Antohe F, Radulescu L, Gafencu A, Ghetie V and Simionescu M (2001). Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol 62: 93–105 PubMedCrossRefGoogle Scholar
  34. McCarthy KM, Lam M, Subramanian L, Shakya R, Wu Z, Newton EE and Simister NE (2001). Effects of mutations in potential phosphorylation sites on transcytosis of FcRn. J Cell Sci 114: 1591–1598 PubMedGoogle Scholar
  35. Praetor A, Ellinger I and Hunziker W (1999). Intracellular traffic of the MHC class I-like IgG Fc receptor, FcRn, expressed in epithelial MDCK cells. J Cell Sci 112(Pt 14): 2291–2299 PubMedGoogle Scholar
  36. Rojas R and Apodaca G (2002). Immunoglobulin transport across polarized epithelial cells. Nat Rev Mol Cell Biol 3: 944–955 PubMedCrossRefGoogle Scholar
  37. Raghavan M, Chen MY, Gastinel LN and Bjorkman PJ (1994). Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand. Immunity 1: 303–315 PubMedCrossRefGoogle Scholar
  38. Ward ES, Zhou J, Ghetie V and Ober RJ (2003). Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol 15: 187–195 PubMedCrossRefGoogle Scholar
  39. Ghetie V and Ward ES (2002). Transcytosis and catabolism of antibody. Immunol Res 25: 97–113 PubMedCrossRefGoogle Scholar
  40. Flessner MF, Lofthouse J and Zakaria ER (1997). In vivo diffusion of immunoglobulin G in muscle: effects of binding, solute exclusion, and lymphatic removal. Am J Physiol 273: H2783–2793 PubMedGoogle Scholar
  41. Hansen RJ and Balthasar JP (2003). Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 92: 1206–1215 PubMedCrossRefGoogle Scholar
  42. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR and Beliles RP (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13: 407–484 PubMedGoogle Scholar
  43. Gerlowski LE and Jain RK (1983). Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 72: 1103–1127 PubMedCrossRefGoogle Scholar
  44. Hahnfeldt P, Panigrahy D, Folkman J and Hlatky L (1999). Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 59: 4770–4775 PubMedGoogle Scholar
  45. Predescu D and Palade GE (1993). Plasmalemmal vesicles represent the large pore system of continuous microvascular endothelium. Am J Physiol 265: H725–733 PubMedGoogle Scholar
  46. Zhou J, Johnson JE, Ghetie V, Ober RJ and Sally Ward E (2003). Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G. J Mol Biol 332: 901–913 PubMedCrossRefGoogle Scholar
  47. Hamby DM (1995). A comparison of sensitivity analysis techniques. Health Phys 68: 195–204 PubMedCrossRefGoogle Scholar
  48. D’Argenio DZ and Schumitzky A (1997). ADAPT II User’s Guide: Pharmacokinetic/Pharmacodynamic systems analysis software. Biomedical Simulation Resource, Los Angeles Google Scholar
  49. Ober RJ, Radu CG, Ghetie V and Ward ES (2001). Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13: 1551–1559 PubMedCrossRefGoogle Scholar
  50. Braeckman R (2000). Pharmacokinetics and pharmacodynamics of protein therapeutics. In: Reid, R (eds) Peptide and protein drug analysis, pp 633–669. Marcel Dekker, New York, NY Google Scholar
  51. Henderson LA, Baynes JW and Thorpe SR (1982). Identification of the sites of IgG catabolism in the rat. Arch Biochem Biophys 215: 1–11 PubMedCrossRefGoogle Scholar
  52. Wright A, Sato Y, Okada T, Chang K, Endo T and Morrison S (2000). In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 10: 1347–1355 PubMedCrossRefGoogle Scholar
  53. Ferl GZ, Kenanova V, Wu AM and DiStefano JJ III (2006). A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther 5: 1550–1558 PubMedCrossRefGoogle Scholar
  54. Ferl GZ, Wu AM and DiStefano JJ III (2005). A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 33: 1640–1652 PubMedCrossRefGoogle Scholar
  55. Blumberg RS, Koss T, Story CM, Barisani D, Polischuk J, Lipin A, Pablo L, Green R and Simister NE (1995). A major histocompatibility complex class I-related Fc receptor for IgG on rat hepatocytes. J Clin Invest 95: 2397–2402 PubMedCrossRefGoogle Scholar
  56. Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS and Lencer WI (2002). Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. [erratum appears in J Exp Med. 2003 Jun 2;197(11):1601]. J Exp Med 196: 303–310 PubMedCrossRefGoogle Scholar
  57. Haymann JP, Levraud JP, Bouet S, Kappes V, Hagege J, Nguyen G, Xu Y, Rondeau E and Sraer JD (2000). Characterization and localization of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol 11: 632–639 PubMedGoogle Scholar
  58. Kobayashi N, Suzuki Y, Tsuge T, Okumura K, Ra C and Tomino Y (2002). FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Am J Physiol Renal Physiol 282: F358–365 PubMedGoogle Scholar
  59. McFarlane AS (1963). Catabolism of plasma proteins. Lancet 1: 131–132 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Department of Pharmaceutical SciencesUniversity at Buffalo, The State University of New York, BuffaloBuffaloUSA

Personalised recommendations